Patents by Inventor Gerhard Zoller

Gerhard Zoller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200229674
    Abstract: A liquid distributor for a liquid-transfer system of a conveyor dishwasher has first, second and third connections. The liquid sprayed in at least one final-rinse zone of the conveyor dishwasher can be fed to the liquid distributor via the first connection, wherein some of the liquid fed to the liquid distributor can be discharged, via the second connection, to a line system which can be connected to the second connection, and wherein the rest of the liquid fed to the liquid distributor can be discharged, via the third connection, to at least one line system which can be connected to the third connection. The liquid distributor has an interchangeable aperture component, which defines the fraction of liquid which is fed to the liquid distributor via its first connection and is to be discharged, via the second connection, to the line system which can be connected to the second connection.
    Type: Application
    Filed: September 20, 2018
    Publication date: July 23, 2020
    Inventors: Frank ZOLLER, Matthias LANGE, Gerhard FREI
  • Patent number: 9029400
    Abstract: The present invention relates to 5-oxoisoxazole derivatives of the formula I, the pharmaceutically usable salts thereof and the use thereof as medicinal substances.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: May 12, 2015
    Assignee: Sanofi
    Inventors: Stefan Petry, Manfred Seidel, Gerhard Zoller, Gunter Müller, Karl-Heinz Baringhaus, Hubert Heuer
  • Patent number: 8921404
    Abstract: The invention relates to azole derivatives of the general formula I as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds of the invention.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Norbert Tennagels
  • Patent number: 8735437
    Abstract: The present invention relates to imidazolidinecarboxamide derivatives of the general formula I, wherein R, R1, R2, X and Y are as defined herein, or pharmaceutically usable salts thereof and the use thereof as medicinal substances.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: May 27, 2014
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Norbert Tennagels
  • Patent number: 8673917
    Abstract: The invention relates to compounds of the formula (I), where the groups R1, M, A, B, D, L, and R have the specified meanings, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treating metabolic syndrome, insulin resistance, obesity, and diabetes.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: March 18, 2014
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Marc Dietrich Voss, Hans Matter, Andreas Herling
  • Patent number: 8642620
    Abstract: The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: February 4, 2014
    Assignee: Sanofi
    Inventors: Harmut Strobel, Paulus Wohlfart, Gerhard Zoller, David William Will
  • Patent number: 8518976
    Abstract: The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 27, 2013
    Assignee: Sanofi
    Inventors: Harmut Strobel, Paulus Wohlfart, Gerhard Zoller, David William Will
  • Patent number: 8470841
    Abstract: Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: June 25, 2013
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Dieter Schmoll, Marco Mueller, Guido Haschke, Ingo Focken
  • Patent number: 8399476
    Abstract: The present invention relates to derivatives of imidazo[1,2-a]pyridines of formula I, in which R, R1 to R4 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of formula I, to pharmaceutical compositions comprising them, and to the use of compounds of formula I for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: March 19, 2013
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Hartmut Strobel, David William Will, Paulus Wohlfart
  • Patent number: 8357698
    Abstract: The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds to treat diabetes mellitus, dyslipidemia and atherosclerotic disorders.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: January 22, 2013
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Hubert Heuer, Norbert Tennagels
  • Patent number: 8304438
    Abstract: The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: November 6, 2012
    Assignee: Sanofi
    Inventors: Hartmut Strobel, Paulus Wohlfart, Heinz-Werner Kleemann, Gerhard Zoller, David William Will
  • Patent number: 8299102
    Abstract: The present invention relates to heteroarylcyclopropanecarboxamides of the formula I, in which Het, X, Ra, Rb, Rc, Rd, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: October 30, 2012
    Assignee: Sanofi
    Inventors: Hartmut Strobel, Paulus Wohlfart, Gerhard Zoller, David William Will
  • Patent number: 8188291
    Abstract: The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: May 29, 2012
    Assignee: Sanofi-Aventis
    Inventors: Hartmut Strobel, Paulus Wohlfart, Heinz-Werner Kleemann, Gerhard Zoller, David William Will
  • Patent number: 8168665
    Abstract: The present invention relates to derivatives of 2-phenyl-benzimidazoles of the formula I, in which X, R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: May 1, 2012
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Hartmut Strobel, David William Will, Paulus Wohlfart
  • Patent number: 8148395
    Abstract: The present invention relates to azolopyridin-3-one derivatives of the general formula I with the meanings indicated in the description, their pharmaceutically usable salts and their use as medicinal substances.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: April 3, 2012
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Muller, Norbert Tennagels
  • Publication number: 20120028986
    Abstract: The invention relates to compounds of the formula (I), where the groups R1, M, A, B, D, L, and R have the specified meanings, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treating metabolic syndrome, insulin resistance, obesity, and diabetes.
    Type: Application
    Filed: September 2, 2009
    Publication date: February 2, 2012
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Zoller, Marc Dietrich Voss, Hans Matter, Andreas Herling
  • Patent number: 8080569
    Abstract: The present invention relates to derivatives of imidazo[2,1-b]thiazoles of formula I, in which R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: December 20, 2011
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Hartmut Strobel, David William Will, Paulus Wohlfart
  • Patent number: 8044050
    Abstract: The present invention relates to derivatives of imidazo[1,2-a]azines of formula I, in which R, R1 to R3, X, Y and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of formula I, to pharmaceutical compositions comprising them, and to the use of compounds of formula I for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: October 25, 2011
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Hartmut Strobel, David William Will, Paulus Wohlfart
  • Publication number: 20110245263
    Abstract: The invention relates to heterocyclic derivatives of formula I wherein R, R1, A, B, D, M, L and n are as defined herein, or their physiologically compatible salts, their pharmaceutical compositions and their uses as SCD1 inhibitors.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Zoller, Marc Dietrich Voss, Stefanie Keil, Andreas Herling, Hans Matter
  • Patent number: 8008331
    Abstract: The invention relates to benzothiazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: August 30, 2011
    Assignee: Sanofi-Aventis
    Inventors: Gerhard Zoller, Stefan Petry, Gunter Müller, Hubert Heuer, Norbert Tennagels